Retrospective study comparing low-dose versus standard dose of bortezomib in patients with multiple myeloma
INTRODUCTION Bortezomib is a selective inhibitor of the proteosoma that is used in multiple myeloma. In combination with other antineoplastic drugs, it has a well-documented impact in progression-free survival rates and overall survival rates with standard doses (1.3-1.5 mg/m2). However, up to 88%...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medwave Estudios Limitada
2015-03-01
|
| Series: | Medwave |
| Online Access: | http://www.medwave.cl/link.cgi/Medwave/Estudios/Investigacion/6098 |